Samsung Biologics
Samsung Biologics, a leading player in the biopharmaceutical industry, is headquartered in Incheon, South Korea (KR). Founded in 2011, the company has rapidly established itself as a key provider of contract development and manufacturing services (CDMO) for biopharmaceuticals, catering to a global clientele. With a focus on monoclonal antibodies and other biologics, Samsung Biologics offers unique solutions that leverage cutting-edge technology and state-of-the-art facilities. The company has achieved significant milestones, including the completion of its third manufacturing plant, which enhances its production capacity and reinforces its market position. Recognised for its commitment to quality and innovation, Samsung Biologics continues to set industry standards, making it a preferred partner for biopharmaceutical companies worldwide.
DitchCarbon Score
How does Samsung Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Samsung Biologics's score of 48 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Samsung Biologics's reported carbon emissions
In 2023, Samsung Biologics reported total carbon emissions of approximately 150,436,000 kg CO2e from Scope 2 and 69,262,000 kg CO2e from Scope 1, alongside Scope 3 emissions of about 528,480,000 kg CO2e. This reflects their ongoing commitment to sustainability and climate action. The company has set ambitious targets to achieve net zero emissions by 2050 or earlier. Key milestones include a reduction of 32% in direct emissions by 2030 and 62% by 2040, using 2022 as the baseline year. Additionally, Samsung Biologics aims to cut supplier emissions by 36% by 2030 and 73% by 2040. Over the years, Samsung Biologics has demonstrated a proactive approach to managing its carbon footprint, with total emissions recorded as follows: 137,718,000 kg CO2e in 2021, 170,080,000 kg CO2e in 2022, and 131,536,000 kg CO2e in 2020. The company continues to focus on reducing its environmental impact across all scopes of emissions, reinforcing its commitment to climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 41,469,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 84,993,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Samsung Biologics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
